Cosmos Health enters warrant exchange at $1.45 strike; provides 2024 growth outlook

Cosmos Health Inc.

Warrant exchange with one holder: new warrants for up to 4,874,126 shares at $1.45 (200% of existing warrants; prior strike $2.75).
Company to register new warrant shares within 30 days; AGP receives $215,000 flat fee plus expenses.
Business update: expects substantial revenue growth from 2023 acquisitions, with forecasts for revenue, gross profit, and EBITDA.
New warrants exercisable for 5 years from shareholder approval, issued under Section 3(a)(9) exemption.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cosmos Health Inc. entered into Warrant Exchange Agreement with one holder of certain Company's warrants (effective 2023-12-28).

Action: entry
Counterparty: one holder of certain Company's warrants
Effective: 2023-12-28

Exact text from the filing

On December 28, 2023, Cosmos Health Inc. (the “Company”) entered into a warrant exchange agreement (the “Warrant Exchange Agreement”) with one holder of certain Company’s warrants issued on July 21, 2023 and December 21, 2022 (the “Existing Warrants”), pursuant to which the holder will receive new warrants (the “New Warrants”) to purchase up to an aggregate 4,874,126 shares of Common Stock, par value $0.001 per share (the “New Warrant Shares”), equal to 200% of the 1,915,323 Warrant Shares and 521,740 Warrant Shares issuable pursuant to the exercise of the Existing Warrants, in consideration for exercising for cash any and all such Existing Warrants.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-009424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.